Largest Carbon Molecules Found on Mars Build The Case For Ancient Life
Chains of up to a dozen carbon atoms have been detected in what appears to have been an ancient lakebed on Mars, contributing to a growing library of compounds that could be a vital clue about the history of life on the red planet.
The finding was made by a sampling instrument on NASA's Curiosity rover, with an international team confirming the results in a laboratory here on Earth. The research was led by analytical chemist Caroline Freissinet from the French National Centre for Scientific Research (CNRS).
While the compounds themselves could have been constructed by non-living processes, the very fact they exist at all demonstrates the rover's ability to identify long organic molecules on the Martian surface.
"The provenance and distribution of these molecules are of high interest in the search for potential biosignatures on Mars," the researchers note in their recently published report.
Curiosity's primary goal is to collect clues that could tell us if Mars ever had life, or if it ever came close.
The rover's steady creep over Gale crater's sedimentary rocks has brought it in contact with a number of curious deposits that include various chlorinated and sulfur-containing organic compounds and nitrates, flagging the possibility more complex indicators of life could also be found in the ancient rock.
The researchers used an experimental procedure involving a chemical enhancer to analyze mineral samples taken from a hole drilled into a mudstone deposit named Cumberland.
The experiment's conditions allowed them to cook off molecular oxygen to limit the risk of combustion when they cranked the temperature to around 850 °C (1,562 °F) for a gas chromatography–mass spectrometry procedure.
Among the readings were several of the longest chains of carbon seen on Mars to date – miniscule concentrations of saturated hydrocarbon chains in the form of decane (C10H22), undecane (C11H24), and dodecane (C12H26).
The researchers conducted a number of analytical experiments under laboratory conditions to show how Mars-like mineral conditions could generate the carbon chains from other organic compounds, including benzoic acid, which was also present in their sample.
In any case, the sample analysis and the laboratory work both strongly point to sizable carbon molecules being present in the Martian mudstone.
If the compounds were indeed present in the rock, there's every possibility they were 'built' from simpler molecules like hydrogen and carbon monoxide without any support from a living organism.
Yet it is tempting to consider other possibilities, including a breakdown of even more complex compounds that may be signs of biology. Our own bodies, for example, contain a rich variety of carboxylic acids of the very kind that may be preserved in the sedimentary rock.
"Although abiotic processes can form these acids, they are considered universal products of biochemistry, terrestrial, and perhaps Martian," the researchers conclude.
At the very least, we now know our current technology is capable of literally scratching the surface of chemistry on Mars.
We're far from determining whether any kind of life is fossilized, or even persisting, deep beneath the surface in places where water might still seep. That will almost certainly require future missions, but those future missions will be informed by findings just like this.
For the time being, nobody can blame us for indulging in a moment of wonder at the possibility that these long chains of carbon were once linked together in a life form that evolved on another world.
This research was published in PNAS.
Mysterious 'Death Star' on The Verge of Exploding Is Hiding a Secret
Asteroid May Not Hit Earth in 2032, But It Will Come Back
The Entire Universe Could Exist Inside a Black Hole – Here's Why
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
2 hours ago
- Yahoo
What does lightning look like from space? See stunning photos from astronauts on ISS
It's safe to say that most of us have seen lightning here on Earth plenty of times – some of us have even been struck by it. But the natural phenomenon is one all but a few select individuals will ever have the chance to see from the vantage of 250 miles in orbit. Fortunately, a few astronauts over the years have been more than willing to generously share a glimpse of crashing lightning as seen from outer space. And you better believe it looks nothing like what we're used to seeing from the ground. The latest images of sky-splitting lightning came courtesy of two NASA astronauts who reached the International Space Station together in March after launching from NASA's Kennedy Space Center near Cape Canaveral, Florida. In May, Nichole Ayers and Anne McClain posted photos on social media site X of lightning roiling far, far beneath them. "This is what lightning looks like from the top down," McClain said in a post shared May 21. Here's a closer look at just what they managed to capture from above Earth's atmosphere. The images McClain and Ayers shared show electrostatic discharges – in other words, lightning – from above the clouds as they orbited in the International Space Station. In Ayers' post on X, she said she first observed lightning May 1 while suited up for a spacewalk outside the orbital outpost. She then managed to capture a few photos the next day, which she shared May 5. "I am so amazed by the view we have up here of our Earth's weather systems," Ayers posted. While it was unclear what part of Earth the lightning was striking in Ayers' photos, McClain said her images were captured over Alabama and Georgia. "Fast and furious, but also an incredible sight!" McClain said. The photos not only reveal the chaotic beauty of lightning, but could provide valuable orbital data to scientists studying the phenomenon back on Earth. Here's a look at some of the astronauts' photos: The photos were captured at speeds of 120 frames per second, with the depicted flashes only taking up one frame. The technique was pioneered by veteran NASA astronaut Don Pettit, who is renowned for his astral photography. Pettit, who had arrived in September 2024 for his third and most recent space station stint, departed April 19, 2025, with two cosmonauts before safely landing in Kazakhstan on his 70th birthday. Ayers and McClain, who also recently made headlines for completing a rare all-female spacewalk, are among seven people living at the International Space Station. The crew of Expedition 73 includes three Americans, three Russian cosmonauts and one Japanese spacefarer from the Japan Aerospace Exploration Agency (Jaxa.) McClain and Ayers are both part of a SpaceX mission known as Crew-10 that reached the space station in March 2025. Their arrival with JAXA astronaut Takuya Onishi and Roscosmos cosmonaut Kirill Peskov paved the way for the NASA astronauts who crewed the doomed Boeing Starliner to depart with the Crew-9 mission. Also at the station is NASA astronaut Jonny Kim, who reached the outpost in April 2025 with cosmonauts Sergey Ryzhikov and Alexey Zubritsky. Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@ This article originally appeared on Florida Today: Lightning from space: Astronauts post stunning weather images on X
Yahoo
2 hours ago
- Yahoo
Sanofi to acquire Blueprint for up to $9.5B
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion. Blueprint's research revolves around an enzyme made by a gene called KIT. This 'tyrosine kinase' enzyme helps control cell development, division and survival, so if it mutates, it can spur the type of uncontrolled cell growth seen in cancer and some rare diseases. Blueprint already has one medicine approved by the Food and Drug Administration, Ayvakit, and is working on a handful of others, two of which are in human testing. The FDA first approved Ayvakit in early 2020 for a rare kind of hard-to-treat gastrointestinal tumor, and specifically for the small subset of adults who have these tumors and certain mutations. Since then, the agency cleared the medicine as a treatment for both the less and more aggressive forms of 'systemic mastocytosis,' an uncommon disorder where a kind of white blood cell known as a mast cell builds up in the bone marrow, digestive tract, skin and other organs. The accumulation can lead to severe inflammation and organ damage. Last year, Blueprint posted $479 million in net product revenue from Ayvakit. The company used to have another marketed cancer drug, Gavreto, which it was co-developing and commercializing with Roche. But Roche ultimately backed away from that alliance, leading Blueprint to sell away rights to Rigel Pharmaceuticals in early 2024. In a statement announcing the deal, Sanofi highlighted the recent trajectory in Ayvakit sales. They were up more than 60%, for example, between the first quarter of 2024 and the same three-month period this year. Blueprint recorded a $67 million net loss in 2024, compared to a more than half-a-billion-dollar net loss in each of the previous two years. The proposed acquisition 'represents a strategic step forward in our rare and immunology portfolios,' Sanofi CEO Paul Hudson said in the Monday statement. 'It enhances our pipeline and accelerates our transformation into the world's leading immunology company.' Hudson added that his company maintains a 'sizeable capacity for further acquisitions.' After being an active dealmaker over the past few years, the French pharmaceutical giant still had close to 8 billion euros in cash and cash equivalents at the end of March. Sanofi bought the diabetes drug developer Provention Bio for almost $3 billion in 2023 and the rare disease-focused Inhibrix for $2.2 billion in 2024. And just last month, it agreed to spend $470 million on Vigil Neuroscience, a Massachusetts-based biotechnology company touting an Alzheimer's disease drug that just finished an early-stage human study. Similar to its Vigil proposal, Sanofi is offering Blueprint investors a so-called contingent value right that could be worth up to $6 per Blueprint share, provided one of the biotech's experimental drugs, 'BLU-808,' hits certain development and regulatory goals. BLU-808 is in mid-stage testing as a possible treatment for chronic hives and an allergy-related condition that causes runny eyes and a congested nose. Blueprint also believes the drug could be useful in treating allergic asthma and 'mast cell activation syndrome.' Another Blueprint drug, elenestinib, is further along, having advanced to a late-stage study for the slower-moving form of systemic mastocytosis. Sanofi's upfront payment of $9.1 billion values Blueprint shares at $129 apiece, reflecting a premium of about 27% from the biotech's closing stock price on Friday. The transaction is expected to close sometime between July and the end of September, according to Sanofi. Andrew Berens, an analyst at the investment firm Leerink Partners, wrote in a note to clients how his team expected Blueprint to land on the 'strategic radar of large pharma' given Ayvakit is on the path to $1 billion or more in annual sales and the company recently raised its financial guidance for this year. However, the deal came sooner than anticipated, ahead of a key data readout for a rival drug from Cogent Biosciences. Cogent's bezuclastinib is also being evaluated as a treatment for systemic mastocytosis, with results set to arrive in the next couple months. Regardless of how strong or weak those results will be, Berens believes they'd serve as a tailwind for Blueprint 'by removing a key overhang and allowing a strategic acquirer to structure a deal based on assumptions about ... market dynamics.' As such, Cogent's data could have propped up Blueprint's share price, 'which may have been an impetus for Sanofi to do the deal now,' Berens posited. Even so, the analyst still sees Sanofi's bid as a positive for Blueprint and this field of research. Cogent shares were down by about 2% late Monday morning. Recommended Reading Blueprint wins key FDA approval for rare disease drug Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
SpaceX will hit $15.5 billion in revenue this year, Elon Musk says
Elon Musk seems to think the sky isn't SpaceX's limit — and maybe not even its revenue ceiling. The CEO said on Tuesday that his company is on track to generate $15.5 billion in revenue in 2025, a leap from last year's estimated $11-13 billion. Musk posted SpaceX's revenue projections on X and added that, in 'perhaps an interesting milestone,' SpaceX's commercial revenue from space will exceed NASA's entire budget in 2026. The company will make about $1.1 billion alone through its work with NASA this year. SpaceX is one of the world's most valuable privately held companies, and its revenue is largely driven by two segments: its launch services and Starlink, its global satellite internet division. In February, Starlink claimed to have over five million customers worldwide; its base reportedly doubled from 2023 to 2024. Musk has said Starlink will go public once cash flow becomes more predictable — but hasn't specified when that might be. Meanwhile, SpaceX completed 134 launches in 2024 and is aiming for as many as 170 this year (it has already launched 62 times in 2025) — more than any other company or government space agency. Most of these are Falcon 9 missions, which have been used to deliver commercial satellites, government payloads, and NASA cargo. The rockets' reusability has been an advantage, and frequent launches have helped SpaceX secure a large share of the global market. But competitors such as Blue Origin and some international players are making progress, meaning the commercial launch market is getting more crowded. Much of the SpaceX's revenue is being plowed directly into the company's Starship program, which Musk sees as the key to interplanetary expansion — namely his plan to colonize Mars. Each Starship launch costs around estimated $100 million; Musk has said his goal is to lower that to around $10 million. But Starship has yet to demonstrate full mission success. A recent launch went father than ever before — but still ended with the rocket spinning out of control. For the latest news, Facebook, Twitter and Instagram. Sign in to access your portfolio